Sotagliflozin considerably reduces coronary heart assaults and strokes in high-risk sufferers with diabetes and kidney illness, providing a brand new remedy choice for cardiovascular safety. Sotagliflozin, a lately FDA-approved drug for treating kind 2 diabetes and kidney illness in sufferers with further cardiovascular threat elements, has been proven to considerably scale back the danger of coronary heart assault and […]
Source link
The experimental drug IC7Fc reduces artery-clogging fat and irritation in mice, pointing to a possible new technique for stopping coronary heart illness. Earlier work linked the experimental drug...
Read more










